The methodology exists today. Organizations that recognize the gap can engage at two levels: as a founding partner shaping what QIS becomes, or through a scoped consulting engagement that proves the gap in their own data. Both lead to the same conversation.
Ten organizations that will define what QIS means in practice. Not customers. Co-authors. Their patient data, their clinical context, and their institutional knowledge shape the methodology alongside ours.
Founding partners receive priority access to the QIS platform before general availability, named acknowledgment in publications and policy submissions, and a voice in the Federal Register submission and rare disease data infrastructure advocacy. Engagement begins with a conversation.
Priority access to the QIS platform before general release. Your use case built first. Your feedback shapes the next iteration.
Your patient population, your clinical context, your institutional data shape the methodology alongside ours. The methodology becomes yours.
Founding partner designation in all QIS publications, presentations, policy submissions, and conference materials. Named on the ATS poster.
Participation in Federal Register submissions (Docket FDA-2026-N-0131), rare disease data infrastructure advocacy, and shared voice at regulatory forums.
If your organization has built or fine-tuned its own LLM, we ingest it as a participating Verity lens. Your model joins the triangulation. Your investment gains leverage it does not have on its own.
Three scoped consulting engagements that prove the methodology in your own environment. Each produces a finding within weeks, not months. Each opens the Founding 10 conversation naturally.
A scoped assessment of your existing quantitative and qualitative data assets. A gap map of what your data holds, what it misses, and what it is worth. Priority recommendations delivered as a written brief.
Pre-protocol qualitative design review for rare disease trials. Dropout prediction framework. Qualitative gap identification against existing trial data. For US and EU sponsors, including EU-CTR compliance support.
Live example · eCOA Exchange #6Validated interview instruments and self-administered surveys built from 23 years inside the PF/ILD patient community. Deployed across three roles: patient, caregiver, clinician. Surfaces the signals that precede dropout.